Infection and Immunity, July 2001, p. 4195-4201, Vol. 69, No. 7
Tuberculosis: Latency and Reactivation
Department of Molecular Genetics and
Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania 15261,1 and Departments of
Medicine and Microbiology and Immunology, Albert Einstein College
of Medicine, Bronx, New York 104612
Tuberculosis is a major cause of
death around the world, with most of the 1.5 million deaths per year
attributable to the disease occurring in developing countries. This
disease is caused by Mycobacterium tuberculosis, an
acid-fast bacillus that is transmitted primarily via the respiratory
route. Infection occurs in the lungs, but the organism can seed any
organ via hematogenous spread. There are various possible outcomes for
a person encountering M. tuberculosis bacilli. First, the
bacillus can be immediately destroyed by the host's innate responses.
However, the innate mechanisms that protect against infection are
largely uncharacterized; obviously, this is a very important area of
study for vaccine development. Second, a proportion of persons infected
with M. tuberculosis develops active tuberculosis within a
finite time frame (1 to 3 years) (74). This group
presumably lacks the ability to both control the initial infection and
develop a protective response in time to prevent disease. Finally, it
is generally thought that the majority of persons infected with
M. tuberculosis have a clinically latent infection; that is,
they are infected and purified protein derivative(PPD)-positive by skin
test but do not present with clinical symptoms and are not contagious
to others. However, a number of studies indicate that some infected
persons revert to a PPD-negative status, giving weight to the argument
that elimination of the organism by the host has occurred (33,
73). In approximately 5 to 10% of latently infected persons,
the infection will reactivate and cause active tuberculosis
(71). It has been estimated that up to one-third of the
world's population is infected with M. tuberculosis, and
this population is an important reservoir for disease reactivation
(21). Understanding latent and reactivation tuberculosis,
at the level of both the host and the bacillus, is crucial to worldwide
control of this disease.
Infection with M. tuberculosis is believed to occur in an
alveolar macrophage initially. The bacteria replicate within
the macrophage and induce cytokines that initiate the
inflammatory response in the lungs. Macrophages and lymphocytes migrate
to the site of infection and form a granuloma (18). The
function of the granuloma is to segregate the infection to prevent
spread to the remainder of the lung and to other organs, as well as to concentrate the immune response directly at the site of infection. The
granuloma is maintained in a persistently infected host, probably due
to chronic stimulation of the immune cells, and forms the basis for a
tuberculous lesion. Live bacilli have been isolated from granulomas or
tubercles in the lungs of persons with clinically inactive
tuberculosis, indicating that the organism can persist in a
granulomatous lesion for many years (57, 67).
At the most fundamental level, latent tuberculosis can be viewed as an
equilibrium between host and bacillus. In response to infection with
M. tuberculosis, most persons mount a robust immune
response, culminating in the formation of a granulomatous lesion that
apparently contains the infection. The host response prevents active
disease from occurring, and the bacterium avoids elimination. In most
cases, the host response is sufficient to forestall active disease for
a lifetime. However, occasionally the immune response fails in some way
and the infection reactivates to cause active disease. There are a
number of important questions that remain to be answered with respect
to latent tuberculosis. How does the host control the initial infection
to prevent disease? What immune factors contribute to establishment of
a latent infection? Which immunologic components are required to
maintain a latent infection and prevent reactivation? How does the
bacterium evade host antimcrobial defenses and survive in the face of a
strong immune response? Is the bacillus dormant, slowly or
intermittently replicating, or metabolically active? All of these
questions impact another question relevant to vaccine development: How
can the immune system be induced to eliminate, rather than just
control, the tubercle bacillus? Otherwise, immune compromise can lead
to reactivation of the infection. A clearer picture of the interactions between host and bacillus during latent or persistent infection is
essential to answering these questions. The present status of research
in these areas is the subject of this review.
Studies of latent tuberculosis have been hampered by the lack of
animal models truly representative of human latent tuberculosis. Of
course, without a concrete picture of human latent M. tuberculosis infection, it is difficult to model it in an animal
system. The most commonly used animal model for studying tuberculosis
is the mouse. When an appropriate dose is used, M. tuberculosis delivered via the aerosol or intravenous route grows
relatively unimpeded in the lungs (and spleen) of mice for the first 2 to 4 weeks (reviewed in reference 59), at which point in
relatively resistant mouse strains (such as C57BL/6) the immune system
controls the growth of the bacteria and bacterial numbers reach a
plateau (~105 to 106 CFU/lung). Of interest
is the failure of the immune response to substantially reduce the
bacterial numbers in the lung or spleen after this point; in fact, a
persistent or chronic infection ensues and is maintained for many
months (27, 58). Despite relatively high levels of
bacteria in the lungs of the mice and pathology associated with the
infection, the mice do not show clinical signs of disease and can
survive for >1 year postinfection. This persistent-infection state has
been used as a model of latent tuberculosis by a number of groups
(1, 27, 54, 58, 70). It is an attractive model in that it
truly represents equilibrium between host and bacillus and in that the
bacterial numbers are controlled by the immune response, which is true
for the human latent infection. Induction of immune compromise results
in reactivation or relapse of the persistent infection. However, the
high bacterial numbers in the lungs of the mice probably are not
reflective of the situation in humans. There are data suggesting that
the bacteria may be in a quiescent state (i.e., not actively
replicating) during the persistent phase (66). This model
has been effective in studying persistent tuberculosis, with some of
the findings from this model applicable to human latent and
reactivation tuberculosis, as described below.
Another mouse latent tuberculosis model was developed by McCune and
colleagues at Cornell University in the 1950s (48-50). The Cornell model involved treating M. tuberculosis-infected
mice with antimycobacterial drugs, which reduced the bacterial burden to undetectable levels. After antibiotic treatment, reactivation of the
infection can occur spontaneously or in response to immunosuppressive agents, such as glucocorticoids. This model is attractive because of
the low bacterial burden in the mice. However, introduction of
antibiotics to effect this reduction in bacterial numbers does not
mimic the situation in natural human latent tuberculosis and may affect
the development of a protective immune response. This is particularly
true for the early studies with this model, where antibiotics were
administered immediately after infection. In addition, the effects of
long-term antibiotics on the growth or survival characteristics of
organisms in vivo introduces an additional variable (69).
A recent publication describes the testing of various modifications of
the Cornell model, with the conclusion being that this model was
technically difficult, expensive, and unpredictable for studies on the
immunologic basis of latent and reactivation tuberculosis
(69). However, others have used variations on this model
to study persistence and reactivation of mycobacteria in the host, as
well as vaccination of latently infected hosts (7, 40, 42, 52,
61).
Other animal models for the study of tuberculosis include guinea pigs,
rabbits, and nonhuman primates, although latency models developed with
these experimental animals have not been widely used at this point.
Despite the difficulty in modeling human latency in experimental
animals, the understanding of both host and microbial factors that
contribute to the establishment and maintenance of a persistent
M. tuberculosis infection has progressed and the information
gathered is pertinent to human latent tuberculosis.
Murine models have been used extensively to delineate the host
factors that are key to controlling the initial infection with M. tuberculosis. Using either gene-deficient (knockout) mice or neutralization with antibodies, various cytokines and cell types have
been demonstrated to be essential to the control of M. tuberculosis. T cells, both CD4+ and CD8+,
participate in protection against tuberculosis (reviewed in reference
24). These cells function to activate and destroy M. tuberculosis-infected macrophages. Production of reactive
nitrogen intermediates (RNI) by induction of nitric oxide synthase
(NOS2) in macrophages is necessary to protect mice against
tuberculosis (11, 43); there is now a fair amount of
evidence to indicate a role for RNI in human tuberculosis as well
(reviewed in reference 10). A pivotal cytokine in the
immune response to this pathogen is gamma interferon (IFN- Tunor necrosis factor alpha (TNF- Both IFN- T cells play an important role in the immune response against M. tuberculosis. Both CD4 and CD8 T cells participate in control of
acute tuberculosis in mice (reviewed in reference 24),
although the relative importance of CD8 T cells is more controversial
(53). In humans, infection with human immunodeficiency
virus (HIV) leads to a loss of CD4 T cells, which is associated with an
increased risk of tuberculosis. While an HIV-negative, PPD-positive
person has a 10% lifetime risk of developing active tuberculosis,
coinfection with M. tuberculosis and HIV carries a 5 to 15%
yearly risk of active tuberculosis (71). It is generally
accepted that a TH1 response, characterized by production of IFN- In a persistent infection in mice, CD4 and CD8 T cells in the lungs
produced IFN- In contrast to the results of studies with the persistent-infection
model, described above, depletion of CD4 T cells in the Cornell model
of latent infection did not result in reactivation (76).
In this same model, depletion of CD8 T cells had a detrimental effect
on the ability of the mice to control the infection (76). Reconciling the differences between the two models and the effects of
each T-cell population on the infection will be important to our
understanding of protective immune responses during latent infection.
The establishment of a persistent infection demands that
a microbe evade and subvert various immune mechanisms that are meant to
eliminate pathogens. In the case of latent tuberculosis, the host
mounts a strong immune response that contains but does not eliminate
the infection. Clearly the host response is effective in containment,
since disruption of immune mechanisms can lead to reactivation of the
quiescent infection, in humans and in animal models. However, the
ability of the organism to survive in the face of a robust response
clearly implicates a series of evasion mechanisms by the pathogen.
Identifying these immune evasion strategies, as well as the
mycobacterial genes involved, is central to our understanding of the
pathogenesis of tuberculosis, as well as to the design of an effective vaccine.
M. tuberculosis-infected macrophages are rather
ineffective at stimulating proliferation of and cytokine production by
Mycobacteria-specific CD4 T cells (5, 35, 72).
Infection of macrophages with M. tuberculosis can
result in down-regulation of major histocompatibility complex class II
expression or presentation (38, 47, 56, 62, 82). Other
studies indicate that M. tuberculosis induces macrophages to produce immunosuppressive cytokines, such as
IL-10 or tumor growth factor beta, and these cytokines impair the
ability of infected macrophages to stimulate T cells
effectively (36, 37, 68). There is also a recent report
indicating that M. tuberculosis-infected macrophages
are refractory to the effects of IFN- The low tissue bacterial burden associated with tuberculous
latency is a major obstacle to characterizing the mechanisms by which
M. tuberculosis persists and reactivates in the host. This difficulty is further compounded by the lack of a much-needed genuine
animal model of latent tuberculosis for stringently testing the
validity of putative mechanisms underlying the persistence of the
tubercle bacillus. Nevertheless, based on results of in vitro
experimentation, various mycobacterial components have been identified
as candidate persistent factors that may play a role in the
establishment of the latent state of infection. More important, existing animal models, particularly those of the mouse, have been
employed to evaluate the significance of these mycobacterial factors in
tuberculous persistence. The use of the low-dose, persistent-infection murine model for tuberculosis, despite certain limitations, has been
particularly useful for elucidating the roles of various M. tuberculosis components in tuberculous persistence. Examination of
M. tuberculosis mutant strains deficient in some of the
putative mycobacterial persistence factors in the chronic murine
tuberculosis model has revealed that such mutants may display no
apparent impairment in survival within the host; alternatively, they
can be defective for growth or persistence. Mutants with growth
impairment, compared to wild-type M. tuberculosis, fail to
attain peak tissue bacillary burden during the initial rapid
replicative phase in the host (16). Persistence mutants,
while exhibiting no growth defect, cannot sustain the peak tissue
bacillary load usually stably maintained by wild-type bacilli for a
prolonged period of time (51). The implications of the in
vivo phenotypes of deficiency in growth and persistence in the context
of latent tuberculosis have yet to be defined. The distinction between
gene functions in terms of growth and persistence is complex, and the
two phenotypes may not be mutually exclusive. Here, we focus on
mycobacterial components that have been shown to adversely affect the
growth or persistence of the tubercle bacillus in the chronic murine
tuberculosis model.
In vitro approach.
The development of methods for the genetic
manipulation of the tubercle bacillus (34, 63) and the
recent availability of the entire M. tuberculosis genome
sequence (13) have provided valuable tools for examining
the mechanisms of tuberculous persistence. Exploiting these tools,
various in vitro systems have been used to define M. tuberculosis components that may contribute to the establishment
of persistence. The two most widely used in vitro systems for
tuberculous latency are modeled, respectively, after anaerobic
conditions and the stationary-growth phase, both of which are generally
thought to be associated with the persistent state.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.7.4195-4201.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
MINIREVIEW
![]()
INTRODUCTION
Top
Introduction
References
![]()
ANIMAL MODELS
![]()
HOST RESPONSES IMPORTANT IN LATENT AND REACTIVATION TUBERCULOSIS
). Mice
deficient in the gene for IFN-
are the most susceptible to fatal
tuberculosis reported to date (15, 23). This cytokine is
responsible for macrophage activation in tuberculosis
(17, 23), including the production of RNI, which is the
only known mechanism by which macrophages can kill intracellular M. tuberculosis (12). However, it
is likely that there are additional mechanisms by which IFN-
contributes to control of tuberculosis, since IFN-
/
mice are more susceptible than mice deficient in NOS2 (11, 23,
43). Humans deficient in the gene for IFN-
or the IFN-
receptor also show enhanced susceptibility to infections with mycobacteria, including M. tuberculosis (reviewed in
reference 60).
) is also a crucial cytokine for
control of acute tuberculosis in mice. Without this cytokine, effective
granuloma formation is diminished and bacterial numbers rapidly
increase, resulting in death of the mice (2, 25). The
effects of TNF-
on the response to M. tuberculosis are
multifaceted and include macrophage activation and RNI
production, granuloma formation, and possibly induction of pathology
(2, 25, 41). A recent study, in which high levels of
TNF-
from recombinant Mycobacterium bovis BCG caused
excessive pathology, supports the hypothesis that the amount of TNF-
in the lungs during infection determines whether the cytokine is
protective or destructive (3). However, recent data
obtained with a persistent infection model indicate that a relative
deficiency of TNF-
can also result in destructive immunopathology
(54). In that study, TNF-
was neutralized in mice that
had previously been infected with M. tuberculosis for 6 months. The loss of TNF-
resulted in a modest increase in bacterial
numbers, but destructive and aberrant pathology discordant with the
number of bacteria in the lungs. Loss of granulomatous structure, as
well as intense inflammation culminating in keratin deposition and
squamous metaplasia in the lungs was observed. The unfocused T-cell and
macrophage infiltrate in the lungs of the anti-TNF-
antibody-treated mice may contribute to the exacerbation of pathology.
Interestingly, significant necrosis was not observed in those mice;
necrosis appears to be correlated with high bacterial numbers in murine
tuberculosis and was present in acute infections in TNF-
-deficient
mice (25). In a modified Cornell model, neutralization of
TNF-
also led to reactivation of infection in a subset of mice
(69). Although bacterial numbers did not reach high levels in these TNF-neutralized and reactivated-infection Cornell model mice,
similar aberrant pathology was observed (54). In a
separate study, mice with a persistent M. tuberculosis
infection were coinfected with adenovirus producing soluble TNF
receptor, effectively neutralizing endogenous TNF in the lungs;
bacterial loads increased dramatically in these mice, and they
succumbed to fatal tuberculosis (1). Together, these
studies revealed a major role for TNF-
in the control of persistent
infection and modulation of the pathologic response to M. tuberculosis. The mechanism by which this cytokine organizes the
localized cellular response in a chronic infection remains to be
determined, but the effects of TNF-
on adhesion molecule, chemokine,
and chemokine receptor expression are likely to contribute to this
function. TNF-
can also affect cytokine expression, which may impact
granuloma formation and function. Anti-TNF-
antibodies are currently
in clinical trails for treating various conditions, including
rheumatoid arthritis. Neutralization of this cytokine should be
approached with caution, since the effects on the immune response to
infections can be profound. In fact, in at least one clinical trial, a
subject receiving anti-TNF-
antibody administration experienced
disseminated M. tuberculosis infection (45).
and TNF-
contribute to resistance to M. tuberculosis in part by their roles in activation of
macrophages and induction of NOS2 expression (reviewed in
reference 22). In a persistent M. tuberculosis
infection, these cytokines continue to be produced in the lungs of
mice, suggesting that continuous macrophage activation is
important in preventing reactivation of the infection
(27). NOS2 mRNA and protein is also present throughout the
persistent infection (27, 70). Inhibition of NOS2 activity
[with aminoguanidine or
L-N6-(1-iminoethyl) lysine (L-NIL)]
in persistently infected mice led to rapid increases in bacterial
numbers in the lungs, although there was little effect observed on
bacterial numbers in the liver and spleens of these mice
(27). This was in contrast to acute infections in
NOS2
/
mice or in mice treated with NOS2 inhibitors,
where increases in bacterial numbers were observed in all three organs
(11, 44). Inhibition of NOS2 activity in
long-term-infected mice treated with antibiotics (a modified Cornell
model) also led to reactivation of the infection (27).
These data indicate that continuous macrophage activation and
RNI production is important in preventing reactivation in the lungs.
The contribution of IFN-
to the control of a persistent infection
has been difficult to test, since the anti-IFN-
antibodies tested
have not been entirely successful, even in an acute infection (J. L. Flynn, unpublished data). However, treatment of Cornell model mice
with anti-IFN-
antibodies did result in reactivation of the latent
infection (69, 76), although there was spontaneous
reactivation, albeit at a slower rate, in the control mice
(69).
by
CD4 T cells, is important in control of M. tuberculosis
infection. The majority of reports on Mycobacteria-specific
CD4 T cells isolated from PPD-positive or active tuberculosis patients
indicate that these cells produce IFN-
; this cytokine production is
believed to be associated with a protective response. Therefore, the
major effector role of CD4 T cells in the response to M. tuberculosis is believed to be production of IFN-
for
activation of macrophages and subsequent destruction of
intracellular bacilli. Studies of M. tuberculosis-infected CD4 T-cell-deficient mice did exhibit an early defect in overall IFN-
production and macrophage activation (9),
and this presumably was responsible for an early increase in bacterial
numbers in the organs. However, as the infection progressed, other
cells, most notably CD8 T cells, were also capable of producing this cytokine in the lungs, and overall IFN-
levels increased to equal those of the wild-type mice. The CD4-T-cell deficient mice still succumbed to the infection, suggesting that early IFN-
production by
CD4 T cells was crucial to the control of the infection. However, a
role for CD4 T cells apart from IFN-
production was also suggested by those and other studies (6, 9).
(70; and J. L. Flynn and N. V. Serbina, unpublished data). Both cell types were found to be present in the granulomatous lesions in humans and mice (26, 31, 65). Depletion of CD4 T cells in a persistently infected mouse caused steady
increases in the numbers of bacteria in all organs and in the death
rates of the mice, demonstrating an essential role for these cells in
control of persistent M. tuberculosis infection (70). However, examination of the mechanism by which these
cells were participating in the prevention of reactivation revealed some surprises. Although CD4 T cells are believed to be major producers
of IFN-
in vivo, depletion of this subset did not result in an
overall decrease in IFN-
production in the lungs. The CD8 T-cell
population produced more IFN-
in the CD4 T-cell-depleted mice, as in
the acute infection model. This CD8 T-cell-derived IFN-
was
sufficient to activate macrophages to produce RNI, as well.
Therefore, the loss of CD4 T cells in the persistently infected mice
did not lead to a deficiency in IFN-
production or NOS2 induction
overall. However, the mice were unable to control the infection, even
in the face of wild-type levels of IFN-
and NOS2. These data
indicated that CD4 T cells have roles in the control of persistent
M. tuberculosis infection that are independent of IFN-
production and that RNI production by macrophages is
insufficient to control a persistent infection. Other possibilities for
the role of CD4 T cells in the control of M. tuberculosis
include production of other cytokines, such as interleukin-2 (IL-2);
effects on other cell populations, such as those of CD8 T cells or B
cells; and other mechanisms of macrophage activation.
![]()
EVASION OF HOST IMMUNE RESPONSES
, a major mediator of
macrophage activation (75). Thus, M. tuberculosis may modulate the macrophage in a variety of
ways to prevent a strong T-cell response from recognizing and
eliminating the intracellular bacilli.
![]()
MYCOBACTERIAL FACTORS IN LATENT INFECTION
knockout mice suggests a link
between the host immune status and the requirement for Icl
(51). This observation implies that the host-bacterium interactions play an important role in the establishment of latent tuberculous infection.
a characteristic of
M. tuberculosis that is potentially virulent. Based on this
hypothesis, Berthet et al. have shown that exported repetitive protein,
an intracellularly exported mycobacterial product, is essential for
optimal growth in vivo (4). Directly examining the
relationship of cell wall mycolic acids and virulence, Dubnau et al.
have recently demonstrated that disruption of the M. tuberculosis
hma gene results in defective oxygenated mycolic acid synthesis
concomitant with deficiency in growth in the mouse (20).
In evaluating the mechanisms for the association of cording and
virulence, Glickman et al. have reported that pcaA, a gene
that encodes mycolic acid proximal cyclopropanation activity and
contributes to the serpentine colonial morphology of M. tuberculosis, is required for virulence and persistence in mice
(28). Importantly, the lungs of mice infected with
wild-type M. tuberculosis and pcaA-negative
mutant revealed markedly different inflammatory reactions, suggesting
that mycolic acid compositions may specifically modulate the host
immune response to M. tuberculosis. These results, together
with the observation that the virulence of Icl-deficient M. tuberculosis can be partially restored in IFN-
knockout mice
(51), underscore the importance of the complex interactions between the host and specific mycobacterial components in
modulating the outcome of tuberculous infection. Finally, through studies designed to examine the effects of iron on the biology of the
tubercle bacillus, mycobacterial factors that may contribute to
persistence have been identified. Manabe et al. (46) used a dominant positive corynebacterial dtxR (diphtheria toxin
repressor) to examine the role of iron in regulating the expression of
virulence genes by M. tuberculosis. This iron-dependent
repressor displays 80% identity in the functional domains with
mycobacterial IdeR (iron-dependent repressor), and M. tuberculosis expressing the dominant-positive DtxR is defective
for growth in the mouse.
In vivo approach. Adoption of signature-tagged mutagenesis (STM) technology has allowed an efficient means of direct in vivo identification of mycobacterial genes essential for survival in the host. In addition, the engineering of in vivo expression technology vectors has made possible in vivo trapping of promoters differentially expressed in the host during infection. Using STM technology, workers in two laboratories have independently identified mycobacterial genes that confer advantages for growth in the mouse (8, 16). Worthy of note, both groups have identified a region in the M. tuberculosis genome containing genes whose functions have been predicted to participate in the biosynthesis of phthiocerol dimycoserosate, a mycobacterial cell wall-associated complex lipid. Indeed, results obtained from biochemical analysis of transposon-mutagenized clones corresponding to this gene cluster have revealed that an intact pps promoter and fadD28 are required for the synthesis of phthiocerol dimycoserosate, and mmpL7 is responsible for transport of this M. tuberculosis lipid (8). STM technology thus provides a highly efficient method to systematically screen for genes critical for optimal growth in vivo. Exploiting the rapidly expanding database on antituberculous drug targets, an inhA-based in vivo expression technology system designed to screen for in vivo expressed mycobacterial genes is being studied. Preliminary results support the feasibility of this approach in trapping M. tuberculosis promoters that are preferentially activated in vivo (E. Dubnau, personal communication). Finally, research in another mycobacterial pathogen M. marinum has demonstrated the feasibility of the use of differential fluorescence induction, a fluorescence-activated cell sorter-based method to identify genes with enhanced expression in vivo (64). Mutation of two genes in M. marinum identified by this method, mag 24-1 and mag 24-3, results in deficient replication inside macrophages. These mutants also appear to be attenuated for their ability to persist in a frog granuloma model. The mag 24-1 and mag 24-3 genes are homologs of the M. tuberculosis PE-PGRS genes, predicted to encode a family of glycine-rich proteins of unknown function. It will be of interest to examine the role of PE-PGRS in the persistence of the tubercle bacillus in vivo.
Clearly, the use of the various in vitro and in vivo strategies described above has facilitated the identification of a rapidly growing list of mycobacterial factors that confer advantages for growth and/or persistence in the host. However, the significance of these factors in contributing to the ability of M. tuberculosis to establish latency remains unknown. Nonetheless, these approaches represent an important and significant first step toward the characterization of M. tuberculosis genes that might contribute directly or indirectly to the persistence of the tubercle bacillus in the host.| |
CONCLUSIONS AND FUTURE STUDIES |
|---|
Latent M. tuberculosis infections present one of the
major obstacles in gaining control over tuberculosis worldwide. Lack of
information about the state of the bacillus during clinical latency
hinders our ability to model latent tuberculosis in a laboratory
setting. Animal models that truly represent human latent tuberculosis
are also difficult to create and study. However, both in vitro and in
vivo systems have been developed which contribute to our current
understanding of latency. Host responses important in controlling the
latent infection may include macrophage activation, maintenance
of granuloma structure, CD4 T cells, CD8 T cells, IFN-
, and TNF-
.
Still to be tested are the contribution of other cytokines or
chemokines and a multitude of other host factors to establishment and
control of a latent tuberculous infection. The sequencing of the
M. tuberculosis genome, as well as exciting new techniques
for genetic manipulation and study of mycobacteria, are providing new
avenues for understanding the changes the bacteria undergo to enter a
persistent state and evade elimination by the robust response of the host.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge support from the National Institutes of Health (AI36990).
We are grateful to the members of the Flynn and Chan labs for helpful discussions and reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Phone: (412) 624-7743. Fax: (412) 648-3394. E-mail: joanne{at}pitt.edu.
Editor: D. A. Portnoy
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Adams, L. B., C. M. Mason, J. K. Kolls, D. Scollard, J. L. Krahenbuhl, and S. Nelson. 1995. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J. Infect. Dis. 171:400-405[Medline]. |
| 2. |
Bean, A. G. D.,
D. R. Roach,
H. Briscoe,
M. P. France,
H. Korner,
J. D. Sedgwick, and W. J. Britton.
1999.
Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.
J. Immunol.
162:3504-3511 |
| 3. | Bekker, L.-G., A. L. Moreira, A. Bergtold, S. Freeman, B. Ryffel, and G. Kaplan. 2000. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent Infect. Immun. 68:6954-6961. |
| 4. |
Berthet, F.-X.,
M. Lagranderie,
P. Gounon,
C. Laurent-Winter,
D. Ensergueix,
P. Chavarot,
F. Thouron,
E. Maranghi,
V. Pelicic,
D. Portnoi,
G. Marchal, and B. Gicquel.
1998.
Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene.
Science
282:759-762 |
| 5. |
Bodnar, K. A.,
N. V. Serbina, and J. L. Flynn.
2001.
Interaction of Mycobacterium tuberculosis with murine dendritic cells.
Infect. Immun.
69:800-809 |
| 6. |
Bonecini-Almeida, M.,
S. Chitale,
I. Boutsikakis,
J. Geng,
H. Doo,
S. He, and J. L. Ho.
1998.
Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes.
J. Immunol.
160:4490-4499 |
| 7. |
Brooks, J. V.,
S. K. Furney, and I. M. Orme.
1999.
Metronidazole therapy in mice infected with tuberculosis.
Antimicrob. Agents Chemother.
43:1285-1288 |
| 8. | Camacho, L. R., D. Ensergueix, E. Perez, B. Gicquel, and C. Guilhot. 1999. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34:257-267[CrossRef][Medline]. |
| 9. |
Caruso, A. M.,
N. Serbina,
E. Klein,
K. Triebold,
B. R. Bloom, and J. L. Flynn.
1999.
Mice deficient in CD4 T cells have only transiently diminished levels of IFN- , yet succumb to tuberculosis.
J. Immunol.
162:5407-5416 |
| 10. | Chan, J., and J. L. Flynn. 2000. Latent and reactivation tuberculosis. Einstein Q. J. Biol. Med. 17:69-77. |
| 11. | Chan, J., K. Tanaka, D. Carroll, J. L. Flynn, and B. R. Bloom. 1995. Effect of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-740[Abstract]. |
| 12. |
Chan, J.,
Y. Xing,
R. Magliozzo, and B. R. Bloom.
1992.
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
J. Exp. Med.
175:1111-1122 |
| 13. | Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544[CrossRef][Medline]. |
| 14. |
Collins, D. M.,
R. P. Kawakami,
G. W. de Lisle,
L. Pascopella,
B. R. Bloom, and W. R. Jacobs, Jr.
1995.
Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex.
Proc. Natl. Acad. Sci. USA
92:8036-8040 |
| 15. |
Cooper, A. M.,
D. K. Dalton,
T. A. Stewart,
J. P. Griffen,
D. G. Russell, and I. M. Orme.
1993.
Disseminated tuberculosis in IFN- gene-disrupted mice J.
Exp. Med.
178:2243-2248.
|
| 16. | Cox, J. S., B. Chen, M. McNeil, and W. R. Jacobs, Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402:79-83[CrossRef][Medline]. |
| 17. |
Dalton, D. K.,
S. Pitts-Meek,
S. Keshav,
I. S. Figari,
A. Bradley, and T. A. Stewart.
1993.
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.
Science
259:1739-1742 |
| 18. |
Dannenberg, A. M., Jr., and G. A. W. Rook.
1994.
Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses dual mechanisms that control bacillary multiplication, p. 459-483.
In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
|
| 19. | Dhillon, J., B. W. Allen, Y.-M. Hu, A. R. M. Coates, and D. A. Mitchison. 1998. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2:736-742[Medline]. |
| 20. | Dubnau, E., J. Chan, C. Raynaud, V. P. Mohan, M.-A. Laneelle, K. Yu, A. Quemard, I. Smith, and M. Daffe. 2000. A mutant strain of Mycobacterium tuberculosis with no oxygenated mycolic acids is attenuated in mice. Mol. Microbiol. 36:630-637[CrossRef][Medline]. |
| 21. |
Dye, C.,
S. Scheele,
R. Dolin,
G. Pathania, and M. Raviglione.
1999.
Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country.
JAMA
282:677-686 |
| 22. | Flynn, J. L., and J. Chan. 2000. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129[CrossRef][Medline]. |
| 23. |
Flynn, J. L.,
J. Chan,
K. J. Triebold,
D. K. Dalton,
T. A. Stewart, and B. R. Bloom.
1993.
An essential role for interferon- in resistance to Mycobacterium tuberculosis infection J.
Exp. Med.
178:2249-2254.
|
| 24. | Flynn, J. L., and J. D. Ernst. 2000. Immune responses in tuberculosis. Curr. Opin. Immunol. 12:432-436[CrossRef][Medline]. |
| 25. |
Flynn, J. L.,
M. M. Goldstein,
J. Chan,
K. J. Triebold,
K. Pfeffer,
C. J. Lowenstein,
R. Schreiber,
T. W. Mak, and B. R. Bloom.
1995.
Tumor necrosis factor- is required in the protective immune response against M. tuberculosis in mice.
Immunity
2:561-572[CrossRef][Medline].
|
| 26. |
Flynn, J. L.,
M. M. Goldstein,
K. J. Triebold,
B. Koller, and B. R. Bloom.
1992.
Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.
Proc. Natl. Acad. Sci. USA
89:12013-12017 |
| 27. |
Flynn, J. L.,
C. A. Scanga,
K. E. Tanaka, and J. Chan.
1998.
Effects of aminoguanidine on latent murine tuberculosis.
J. Immunol.
160:1796-1803 |
| 28. | Glickman, M., J. S. Cox, and W. R. Jacobs, Jr. 2000. A novel mycolic acid cyclopropane synthetase is required for cording, persistence and virulence of Mycobacterium tuberculosis. Mol. Cell 5:717-727[CrossRef][Medline]. |
| 29. | Gomez, J. E., J. M. Chen, and W. R. Bishai. 1997. Sigma factors of Mycobacterium tuberculosis. Tuber. Lung Dis. 78:175-183[CrossRef][Medline]. |
| 30. | Gomez, M., L. Doukhan, G. Nair, and I. Smith. 1998. sigA is an essential gene in Mycobacterium smegmatis. Mol. Microbiol. 29:617-628[CrossRef][Medline]. |
| 31. |
Gonzalez-Juarrero, M.,
O. C. Turner,
J. Turner,
P. Marietta,
J. V. Brooks, and I. M. Orme.
2001.
Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis.
Infect. Immun.
69:1722-1728 |
| 32. |
Graham, J. E., and J. E. Clark-Curtiss.
1999.
Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS) Proc.
Natl. Acad. Sci. USA
96:11554-11559 |
| 33. | Grzybowski, S., and E. A. Allen. 1964. The challenge of tuberculosis in decline. A study based on the epidemiology of tuberculosis in Ontario, Canada. Am. Rev. Resp. Dis. 90:707-720. |
| 34. | Hatfull, G. F., and W. R. Jacobs, Jr. (ed.). 2000. Molecular genetics of mycobacteria. ASM Press, Washington, D.C. |
| 35. |
Hirsch, C. S.,
J. J. Ellner,
R. Blinkhorn, and Z. Toossi.
1997.
In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta.
Proc. Natl. Acad. Sci. USA
94:3926-3931 |
| 36. |
Hirsch, C. S.,
R. Hussain,
Z. Toosi,
G. Dawood,
F. Shahid, and J. J. Ellner.
1996.
Cross-modulation by transforming growth factor in human tuberculosis: suppression of antigen-driven blastogenesis and interferon production Proc.
Natl. Acad. Sci. USA
93:3193-3198 |
| 37. |
Hirsch, C. S.,
T. Yoneda,
L. Averill,
J. J. Ellner, and Z. Toossi.
1994.
Enhancement of intracellular growth of Mycobacterium tuberculosis in human monoclytes by transforming growth factor- 1.
J. Infect. Dis.
170:1229-1237[Medline].
|
| 38. | Hmama, Z., R. Gabathuler, W. A. Jefferies, G. Dejong, and N. E. Reiner. 1998. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers J. Immunol. 161:4882-4893. |
| 39. |
Höner zu Bentrup, K.,
A. Miczak,
D. L. Swenson, and D. G. Russell.
1999.
Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis.
J. Bacteriol.
181:7161-7167 |
| 40. | Jagannath, C., H. Hoffmann, E. Sepulveda, J. K. Actor, R. A. Wetsel, and R. L. Hunter. 2000. Hypersusceptibility of A/J mice to tuberculosis is in part due to a deficiency of the fifth complement component (C5). Scand. J. Immunol. 52:369-379[CrossRef][Medline]. |
| 41. | Kindler, V., A.-P. Sappino, G. E. Grau, P.-F. Piguet, and P. Vassalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740[CrossRef][Medline]. |
| 42. | Lowrie, D. B., R. E. Tascon, V. L. D. Bonato, V. M. F. Lima, L. H. Faccioli, E. Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling, and C. L. Silva. 1999. Therapy of tuberculosis in mice by DNA vaccination. Nature 400:269-271[CrossRef][Medline]. |
| 43. |
MacMicking, J.,
R. J. North,
R. LaCourse,
J. S. Mudgett,
S. K. Shah, and C. F. Nathan.
1997.
Identification of nitric oxide synthase as a protective locus against tuberculosis.
Proc. Natl. Acad. Sci. USA.
94:5243-5248 |
| 44. | MacMicking, J. D., C. Nathan, G. Hom, N. Chartrain, M. Trumbauer, K. Stevens, Q.-W. Xie, K. Sokol, D. S. Fletcher, N. Hutchinson, H. Chen, and J. S. Mudgett. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-650[CrossRef][Medline]. |
| 45. | Maini, R., E. W. St. Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldman, and P. Lipsky. 1999. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932-1939[CrossRef][Medline]. |
| 46. |
Manabe, Y. C.,
B. J. Saviola,
L. Sun,
J. R. Murphy, and W. R. Bishai.
1999.
Attenuation of virulence in Mycobacterium tuberculosis expressing a constitutively active iron repressor.
Proc. Nat. Acad. Sci. USA
96:12844-12848 |
| 47. |
Mazzaccaro, R. J.,
M. Gedde,
E. R. Jensen,
H. M. van Santem,
H. L. Ploegh,
K. L. Rock, and B. R. Bloom.
1996.
Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection.
Proc. Natl. Acad. Sci. USA
93:11786-11791 |
| 48. | McCune, R. M., F. M. Feldman, and W. McDermott. 1966. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123:469-486[Abstract]. |
| 49. | McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445-468[Abstract]. |
| 50. | McCune, R. M., R. Tompsett, and W. McDermott. 1957. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763-802. |
| 51. | McKinney, J. D., K. Honer zu Bentrup, E. J. Munoz-Elias, A. Miczak, B. Chen, W.-T. Chan, D. Swenson, J. C. Sacchettini, W. R. Jacobs, Jr., and D. G. Russell. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735-738[CrossRef][Medline]. |
| 52. |
Miyazaki, E.,
R. E. Chaisson, and W. R. Bishai.
1999.
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Antimicrob. Agents Chemother.
43:2126-2130 |
| 53. |
Mogues, T.,
M. E. Goodrich,
L. Ryan,
R. LaCourse, and R. J. North.
2001.
The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice.
J. Exp. Med.
193:271-280 |
| 54. |
Mohan, V. P.,
C. A. Scanga,
K. Yu,
H. M. Scott,
K. E. Tanaka,
E. Tsang,
J. L. Flynn, and J. Chan.
2001.
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology.
Infect. Immun.
69:1847-1855 |
| 55. | Murthy, P. S., M. Sirsi, and T. Ramakrishnan. 1973. Effect of age on the enzymes of tricarboxylic acid and related cycles in Mycobacterium tuberculosis H37Rv. Am. Rev. Respir. Dis. 108:689-690[Medline]. |
| 56. | Noss, E. H., C. V. Harding, and W. H. Boom. 2000. Mycobacterium tuberculosis inhibits MHC Class II antigen processing in murine bone marrow macrophages Cell. Immunol. 201:63-74. |
| 57. | Opie, E. L., and J. D. Aronson. 1927. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch. Path. Lab. Med. 4:1. |
| 58. | Orme, I. M. 1988. A mouse model of the recrudescence of latent tuberculosis in the elderly Am. Rev. Respir. Dis. 137:716-718. |
| 59. | Orme, I. M., and F. M. Collins. 1994. Mouse model of tuberculosis, p. 113-134. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C. |
| 60. | Ottenhof, T. H., D. Kumararatne, and J. L. Casanova. 1998. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol. Today 19:491-494[CrossRef][Medline]. |
| 61. | Pai, S. R., J. K. Actor, E. Sepulveda, R. L. Hunter, Jr., and C. Jagannath. 2000. Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA. Microb. Pathogen. 28:335-342[CrossRef][Medline]. |
| 62. |
Pancholi, P.,
A. Mirza,
V. Schauf,
R. M. Steinman, and N. Bhardwaj.
1993.
Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages.
Infect. Immun.
61:5326-5332 |
| 63. | Pelicic, V., J.-M. Reyrat, and B. Gicquel. 1998. Genetic advances for studying Mycobacterium tuberculosis pathogenicity. Mol. Microbiol. 28:413-420[CrossRef][Medline]. |
| 64. |
Ramakrishnan, L.,
N. A. Federspeil, and S. Falkow.
2000.
Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family.
Science
288:1436-1439 |
| 65. | Randhawa, P. S. 1990. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 22:153-155[Medline]. |
| 66. | Rees, R. J. W., and D. Hart. 1961. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Brit. J. Exp. Pathol. 42:83-88[Medline]. |
| 67. | Robertson, H. E. 1933. Persistence of tuberculous infection. Am. J. Pathol. 9:711. |
| 68. |
Rojas, M.,
M. Olivier,
P. Gross,
L. F. Barrera, and L. F. Garcia.
1999.
TNF- and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages.
J. Immunol.
162:6122-6131 |
| 69. |
Scanga, C. A.,
V. P. Mohan,
H. Joseph,
K. Yu,
J. Chan, and J. L. Flynn.
1999.
Reactivation of latent tuberculosis: variations on the Cornell murine model.
Infect. Immun.
67:4531-4538 |
| 70. |
Scanga, C. A.,
V. P. Mohan,
K. Yu,
H. Joseph,
K. Tanaka,
J. Chan, and J. L. Flynn.
2000.
Depletion of CD4+ T cells causes reactivation of murine persistent tuberculosis despite continued expression of IFN- and NOS2.
J. Exp. Med.
192:347-358 |
| 71. | Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Freidland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550[Abstract]. |
| 72. |
Serbina, N. V., and J. L. Flynn.
1999.
Early emergence of CD8+ T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice.
Infect. Immun.
67:3980-3988 |
| 73. | Stead, W. W., and J. P. Lofgren. 1983. Does the risk of tuberculosis increase in old age? J. Infect. Dis. 147:951-955[Medline]. |
| 74. | Styblo, K. 1980. Recent advances in epidemiological research in tuberculosis. Adv. Tuberc. Res. 20:1-63[Medline]. |
| 75. |
Ting, L. M.,
A. C. Kim,
A. Cattamanchi, and J. D. Ernst.
1999.
Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1.
J. Immunol.
163:3898-3906 |
| 76. | van Pinxteren, L. A. H., J. P. Cassidy, B. H. C. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30:3689-3698[CrossRef][Medline]. |
| 77. | Wayne, L. G. 1976. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am. Rev. Respir. Dis. 114:807-811[Medline]. |
| 78. |
Wayne, L. G.
1977.
Synchronized replication of Mycobacterium tuberculosis.
Infect. Immun.
17:528-530 |
| 79. |
Wayne, L. G., and H. A. Sramek.
1994.
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
38:2054-2058 |
| 80. |
Wayne, L. G., and K. Y. Lin.
1982.
Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions.
Infect. Immun.
37:1042-1049 |
| 81. | Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069[Abstract]. |
| 82. |
Wojciechowski, W.,
J. DeSanctis,
E. Skamene, and D. Radzioch.
1999.
Attenuation of MHC Class II expression in macrophages infected with Mycobacterium bovis BCG involves class II transactivator and depends on the Nramp1 gene.
J. Immunol.
163:2688-2696 |
This article has been cited by other articles:
| ||||||||||||||||||||